Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer

Table 2 Combination of test for various molecular markers

Combination of tests			95% CI	P	Youden'sindex
K-ras + LOH 9p	Sensitivity	92%	85%-99%	< 0.001	57%
	Specificity	64%	53%-75%
K-ras + LOH 18q	Sensitivity	92%	85%-99%	< 0.001	49%
	Specificity	57%	45%-69%
LOH 9p + LOH 18q	Sensitivity	92%	85%-99%	< 0.01	34%
	Specificity	43%	31%-55%
p16 + LOH 9p	Sensitivity	84%	74%-94%	< 0.001	49%
	Specificity	64%	53%-75%
K-ras + p53	Sensitivity	74%	65%-83%	< 0.001	64%
	Specificity	90%	85%-95%
K-ras + LOH 9p	Sensitivity	96%	92%-100%	< 0.001	39%
+ LOH 18q	Specificity	43%	31%-55%
K-ras + p16	Sensitivity	92%	85%-99%	< 0.001	57%
+ LOH 9p	Specificity	64%	53%-75%
p53 + LOH 9p	Sensitivity	92%	85%-99%	< 0.001	35%
+ LOH 18q	Specificity	43%	31%-55%